| Literature DB >> 34997047 |
Kiyonori Kobayashi1, Masato Mutsuga2, Akihiko Usui2.
Abstract
We examined the relationship between leg extensor muscle strength (LEMS) at discharge and rehospitalization within 1 year in patients with a newly implanted ventricular assist device (VAD). This study included 28 patients who had received a VAD at our institution between October 2013 and February 2019, all of whom had been discharged for 1 year. The patients were divided into two groups according to their LEMS at discharge (higher strength [group H] and lower strength [group L]), based on the median value of the 55.2 kg-force (kgf)/body weight (BW) equation. Exercise performance parameters (e.g., grip strength, 6-min walk distance, and peak VO2) and laboratory data concerning nutritional status were also collected. Nine patients (64.3%) in group L were rehospitalized within 1 year after discharge. The rehospitalization rate was significantly higher in group L than group H (p = 0.020). Compared with discharge, patients exhibited higher grip strength (56.3 vs. 48.6 kg/BW, respectively; p = 0.011), 6-min walk distances (588 vs. 470 m, respectively; p = 0.002), and peak VO2 (15.4 vs. 11.9 mL/min/kg, respectively; p < 0.001) at 1 year after discharge. However, the LEMS (57.4 vs. 58.0 kgf/BW, respectively; p = 0.798) did not increase after discharge in VAD patients who avoided rehospitalization. LEMS at discharge was associated with rehospitalization after VAD surgery; a high LEMS improves the likelihood of avoiding rehospitalization.Entities:
Mesh:
Year: 2022 PMID: 34997047 PMCID: PMC8741760 DOI: 10.1038/s41598-021-04002-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Relationship between leg strength at discharge and the rate of rehospitalization within 1 year of discharge.
Preoperative characteristics.
| Overall ( | High leg strength ( | Low leg strength ( | |||||
|---|---|---|---|---|---|---|---|
| Age (years) | 44.4 ± 14.1 | 46.9 ± 12.0 | 0.250 | ||||
| Men/women | 12/2 | 11/3 | 0.500 | ||||
| Etiology of heart failure | 0.738 | ||||||
| Dilated cardiomyopathy | 9 | 10 | |||||
| Ischemic cardiomyopathy | 3 | 2 | |||||
| Others | 2 | 2 | |||||
| INTERMACS profile | 0.649 | ||||||
| 1 | 3 | 4 | |||||
| 2 | 2 | 3 | |||||
| 3 | 9 | 6 | |||||
| 4 | 0 | 1 | |||||
| Strategy used for device implantation | 1.000 | ||||||
| Bridge to transplant | 11 | 11 | |||||
| Bridge to bridge | 3 | 3 |
INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support, IQR interquartile range, BMI body mass index, BW body weight.
Comparison of characteristics between the high and low leg strength groups at discharge.
| Overall ( | High leg strength ( | Low leg strength ( | |||||
|---|---|---|---|---|---|---|---|
| Median | IQR | Range | Median | IQR | Range | ||
| Postoperative length of stay (days) | 82 | 85.5 | 52–324 | 99 | 60.5 | 61–282 | 0.800 |
| Echocardiography at discharge | |||||||
| LVEF (%) | 27.4 | 24.0 | 7.6–49.0 | 23.4 | 9.0 | 4.6–46.5 | 0.564 |
| LVDd (mm) | 56.3 | 16.7 | 37.9–86.3 | 55.2 | 16.6 | 32.2–77.0 | 0.880 |
| LVDs (mm) | 48.5 | 21.7 | 32.0–81.6 | 50.3 | 16.3 | 28.3–74.0 | 0.967 |
| Laboratory data at discharge | |||||||
| Serum albumin (g/dL) | 3.8 | 1.0 | 2.4–4.8 | 3.9 | 0.8 | 2.1–4.4 | 1.000 |
| Serum creatinine (mg/dL) | 0.85 | 0.21 | 0.48–1.38 | 0.77 | 0.29 | 0.51–1.58 | 0.835 |
| Serum sodium (mEq/L) | 139 | 3 | 137–142 | 140 | 3 | 137–143 | 0.209 |
| Aspartate aminotransferase (IU/I) | 20 | 5 | 13–33 | 20 | 7 | 13–34 | 0.445 |
| Total bilirubin (mg/dL) | 0.6 | 0.3 | 0.4–1.5 | 0.8 | 0.4 | 0.4–1.6 | 0.463 |
| C-reactive protein (mg/dL) | 0.20 | 0.44 | 0.07–11.26 | 0.43 | 0.43 | 0.04–4.41 | 0.475 |
| Plasma BNP (pg/mL) | 181.3 | 229.2 | 40.7–836.7 | 141.0 | 267.7 | 24.7–853.8 | 0.805 |
| BMI (kg/m2) at discharge | 20.8 | 2.9 | 16.4–26.2 | 19.5 | 2.8 | 16.1–24.1 | 0.944 |
| Rate of change in BMI (%) | 101.6 | 6.7 | 79.8–114.9 | 97.2 | 11.0 | 83.7–109.0 | 0.415 |
| Physical function at discharge | |||||||
| Grip strength (kgf/BW) | 51.9 | 10.9 | 38.3–62.5 | 44.0 | 10.8 | 22.9–75.9 | 0.919 |
| Rate of change in grip strength (%) | 97.6 | 25.6 | 76.7–140.3 | 106.7 | 12.5 | 91.5–141.1 | 0.168 |
| Leg strength (kgf/BW) | 63.9 | 16.6 | 55.4–90.1 | 51.4 | 7.1 | 18.3–54.9 | 0.024 |
| Rate of change in leg strength (%) | 132.6 | 93.2 | 82.2–321.9 | 130.4 | 69.4 | 72.0–204.8 | 0.218 |
| Peak VO2 (mL/kg/min) | 11.7 | 3.1 | 8.9–23.3 | 12.0 | 5.1 | 7.5–16.6 | 0.956 |
| 6-min walking distance (m) | 465 | 70 | 310–600 | 440 | 206 | 230–600 | 0.296 |
IQR interquartile range, BW body weight, BMI body mass index, LVEF left ventricular ejection fraction, LVDd left ventricular diastolic diameter, LVDs left ventricular systolic diameter, BNP brain natriuretic peptide.
Comparison of data between the high and low leg strength groups at 1 year after discharge.
| Overall ( | High leg strength ( | Low leg strength ( | |||||
|---|---|---|---|---|---|---|---|
| Readmission rate, | 3 (21.4) | 9 (64.3) | 0.022 | ||||
IQR interquartile range, BW body weight, BMI body mass index, LVEF left ventricular ejection fraction, LVDd left ventricular diastolic diameter, LVDs left ventricular systolic diameter, BNP brain natriuretic peptide.
Figure 2Comparison of physical function between the high and low leg strength groups.
Figure 3Comparison of physical function between patients with and without readmission.
Stepwise liner regression analysis of variables associated with leg muscle strength in VAD patients (n = 28).
| Total bilirubin | BNP | AR | |||
|---|---|---|---|---|---|
| SC | SC | SC | |||
| –0.408 | 0.039 | – | – | – | – |
| –0.442 | 0.017 | 0.403 | 0.028 | – | – |
| –0.492 | 0.006 | 0.397 | 0.020 | 0.353 | 0.038 |
SC standard coefficient, BNP brain natriuretic peptide, AR aortic regurgitation severity.
Changes in physical function in left VAD patients who avoided rehospitalization.
| Patients without readmission ( | At discharge | One year after discharge | |||||
|---|---|---|---|---|---|---|---|
| Median | IQR | Range | Median | IQR | Range | ||
| BW (kg) | 59.4 | 6.4 | 49.2–83.4 | 66.5 | 22.3 | 56.0–90.2 | < 0.001 |
| BMI (kg/m2) | 20.2 | 3.5 | 16.4–26.2 | 23.9 | 7.4 | 18.1–30.1 | 0.004 |
| Echocardiography | |||||||
| LVEF (%) | 23.4 | 15.4 | 4.6–44.8 | 17.3 | 14.2 | 3.6–53.9 | 0.863 |
| LVDd (mm) | 69.4 | 19.7 | 41.0–86.3 | 68.9 | 20.3 | 46.8–92.5 | 0.089 |
| LVDs (mm) | 62.8 | 22.4 | 32.0–81.6 | 62.5 | 21.6 | 35.6–91.0 | 0.137 |
| AR (0/I/II/III/IV) | (1 / 10 / 3 / 0/ 0) | (2 / 7 / 4 / 1/ 0) | 0.763 | ||||
| Mitral regurgitation severity (0/I/II/III/IV) | (4 / 5 / 5 / 0/ 0) | (6 / 2 / 5 / 1/ 0) | 1.000 | ||||
| Laboratory data | |||||||
| Serum albumin (g/dL) | 3.8 | 0.8 | 2.4–4.7 | 4.3 | 0.4 | 3.5–4.9 | 0.003 |
| Serum creatinine (mg/dL) | 0.78 | 0.20 | 0.53–1.12 | 0.84 | 0.16 | 0.54–1.20 | 0.017 |
| Serum sodium (mEq/L) | 139 | 4 | 137–142 | 139 | 2 | 136–141 | 0.816 |
| Aspartate aminotransferase (IU/I) | 20 | 5 | 13–34 | 23 | 9 | 16–41 | 0.211 |
| Total bilirubin (mg/dL) | 0.6 | 0.6 | 0.4–1.6 | 0.8 | 0.4 | 0.4–2.5 | 0.028 |
| C-reactive protein (mg/dL) | 0.40 | 0.91 | 0.07–11.26 | 0.17 | 0.25 | 0.03–2.39 | 0.008 |
| Plasma BNP (pg/mL) | 194.6 | 319.8 | 24.7–476.7 | 99.3 | 255.7 | 9.4–450.1 | 0.158 |
| Physical function | |||||||
| Grip strength (kgf/BW) | 48.6 | 11.9 | 22.9–75.9 | 56.3 | 17.2 | 27.0–80.8 | 0.011 |
| Leg strength (kgf/BW) | 58.0 | 12.4 | 18.3–83.0 | 57.4 | 15.5 | 23.4–94.5 | 0.793 |
| Peak VO2 (mL/kg/min) | 11.9 | 3.7 | 8.9–23.3 | 15.4 | 5.8 | 10.8–25.0 | < 0.001 |
| 6-min walking distance (m) | 470 | 160 | 350–600 | 588 | 100 | 400–715 | 0.002 |
VAD ventricular assist device, IQR interquartile range, BW body weight, BMI body mass index, LVEF left ventricular ejection fraction, LVDd left ventricular diastolic diameter, LVDs left ventricular systolic diameter, AR aortic regurgitation severity, BNP brain natriuretic peptide.
Figure 4Comparison of physical function between discharge and 1 year after discharge in patients who avoided rehospitalization.